Alnylam Pharma (ALNY) Tops Q1 EPS by 37c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 +2.99%
Revenue Growth %: +70.6%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +70.6%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.52), $0.37 better than the analyst estimate of ($1.89). Revenue for the quarter came in at $99.5 million versus the consensus estimate of $91.56 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Hermès can regain momentum despite China weakness, Jefferies says
- NVE Corporation names new CEO and expands board to seven members
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
